imvigor010 & imvigor011: ctdna as a response biomarker for adjuvant atezolizumab in high-risk mibc
Published 2 years ago • 158 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
4:43
imvigor011: atezolizumab for ctdna-positive patients with high-risk muscle invasive bladder cancer
-
3:42
imbrave050: adjuvant atezolizumab with bevacizumab in high-risk hcc
-
2:52
pd-l1 and tmb as biomarkers in the imvigor211 trial of atezolizumab vs. chemo for bladder cancer
-
1:53
the clinical use of ctdna as a biomarker in tnbc
-
0:50
emerging role of adjuvant immunotherapy in oncology
-
1:57
ctdna, a biomarker of residual disease and tumor response in gastrointestinal cancers
-
0:16
imvigor 210 results in metastatic urothelial carcinoma
-
0:31
unmet needs in the use of circulating tumor cells for prostate cancer
-
0:17
micro medical paediatric adaptor for micro medical spirometers psa1100
-
1:45
mechanism of action of the adenovirus oncolytic virus cg0070 plus pembrolizumab in bladder cancer
-
3:41
cdt 114
-
0:08
artificial intelligence in medicine | healthcare hot topics
-
3:04
first real-world ctdna analysis of oligometastic crc
-
0:49
proteomic markers after injections of av-gbm-1
-
4:07
accomodative iol
-
2:29
(clonevo): cell cycle inhbition to target the evolution of urothelial cancer
-
0:44
aquilion one, whole brain perfusion - srinivasan mukundan, md, phd
-
4:03
cdt 107
-
7:11
tumor immunogenicity biomarkers: the potential of immunoscore ic® (cd8/pdl1) in drug development